Mercer Global Advisors
ALDX icon

Mercer Global Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Mercer Global Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$63.8K Buy
37,742
+27,171
+257% +$119K ﹤0.01% 3100
2025
Q4 		$54.8K Sell
10,571
-3,814
-27% -$19.6K ﹤0.01% 2785
2025
Q3 		$75.1K Buy
+14,385
New +$75K ﹤0.01% 2561

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mercer Global Advisors's ALDX Position: Q1 2026 in Review

Mercer Global Advisors increased its Aldeyra Therapeutics (ALDX) stake by 257% in Q1 2026, buying an estimated $119K and bringing the position to 37,742 shares worth $63.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3100.

Mercer Global Advisors first reported a position in ALDX in Q3 2025 and has held it in 3 quarters since. The position peaked at $75.1K in Q3 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Mercer Global Advisors held 37,742 shares of Aldeyra Therapeutics worth $63.8K as of Q1 2026.
  • Mercer Global Advisors bought 27,171 Aldeyra Therapeutics shares in Q1 2026, an estimated $119K.
  • Aldeyra Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #3100 holding.
  • Mercer Global Advisors first reported a position in Aldeyra Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Mercer Global Advisors's Aldeyra Therapeutics position peaked at $75.1K in Q3 2025.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.